Ethical Considerations in Psychopharmacological Research Involving Children and Adolescents

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2003 Apr 5

PMID 12677353

Citations 12

Authors

Benedetto Vitiello

Affiliations

Soon will be listed here.

Abstract

Rationale: Increased community utilization of psychotropic medications among children has brought attention to pediatric psychopharmacology research and associated ethical issues.

Objectives: To discuss ethical aspects of child participation in psychopharmacology protocols.

Methods: Selective review of relevant scientific and regulatory literature.

Results: Efficacy and safety of psychotropics in children cannot be entirely inferred from adult data and direct participation of children in research is necessary. Child research must follow special regulations that are in addition to those common to all human research. For research with prospect of direct benefit, a critical factor is whether the risk/benefit ratio is favorable to the participating child. For research without such a prospect, the concepts of minimal risk and minor increase over minimal risk apply. However, the interpretation and application of these principles to specific protocols vary across settings and among ethics committees. Thus far, little empirical investigation has been conducted on children and parents' motivation for research participation, effectiveness of the informed consent and assent procedures, possibility of persistent consequences of exposure to experimental treatments and placebo, and validation of the concepts of minimal risk and minor increase over minimal risk.

Conclusions: Research on human subject issues relevant to child participation is a promising approach to improving ethical methods and procedures of pediatric psychopharmacology.

Citing Articles

Assent in applied behaviour analysis and positive behaviour support: ethical considerations and practical recommendations.

Breaux C, Smith K Int J Dev Disabil. 2023; 69(1):111-121.

PMID: 36743317 PMC: 9897747. DOI: 10.1080/20473869.2022.2144969.

A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.

Eugene Arnold L, Ober N, Aman M, Handen B, Smith T, Pan X J Child Adolesc Psychopharmacol. 2018; 28(5):322-330.

PMID: 29694241 PMC: 5994674. DOI: 10.1089/cap.2017.0134.

National Human Research Ethics: A Preliminary Comparative Case Study of Germany, Great Britain, Romania, and Sweden.

Gallagher B, Berman A, Bieganski J, Jones A, Foca L, Raikes B Ethics Behav. 2016; 26(7):586-606.

PMID: 27746664 PMC: 5044765. DOI: 10.1080/10508422.2015.1096207.

Exercise for adolescents with depressive disorders: a feasibility study.

Dopp R, Mooney A, Armitage R, King C Depress Res Treat. 2012; 2012:257472.

PMID: 22888415 PMC: 3409521. DOI: 10.1155/2012/257472.

Ethics of involving children in health-related research: applying a decision-making framework to a clinical trial.

Kelly B, MacKay-Lyons M Physiother Can. 2011; 62(4):338-46.

PMID: 21886373 PMC: 2958080. DOI: 10.3138/physio.62.4.338.

References

Charney D, Nemeroff C, Lewis L, Laden S, Gorman J, Laska E . National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry. 2002; 59(3):262-70. DOI: 10.1001/archpsyc.59.3.262. View

Khan A, Warner H, Brown W . Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 2000; 57(4):311-7. DOI: 10.1001/archpsyc.57.4.311. View

Emanuel E, Wendler D, Grady C . What makes clinical research ethical?. JAMA. 2000; 283(20):2701-11. DOI: 10.1001/jama.283.20.2701. View

Zito J, Safer D, dosReis S, Gardner J, Soeken K, Boles M . Rising prevalence of antidepressants among US youths. Pediatrics. 2002; 109(5):721-7. DOI: 10.1542/peds.109.5.721. View

Vitiello B . Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics. 2001; 108(4):983-9. DOI: 10.1542/peds.108.4.983. View

Clarke G, Rohde P, Lewinsohn P, Hops H, Seeley J . Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry. 1999; 38(3):272-9. DOI: 10.1097/00004583-199903000-00014. View

Coyle J . Psychotropic drug use in very young children. JAMA. 2000; 283(8):1059-60. DOI: 10.1001/jama.283.8.1059. View

McCarthy A, Richman L, Hoffman R, Rubenstein L . Psychological screening of children for participation in nontherapeutic invasive research. Arch Pediatr Adolesc Med. 2001; 155(11):1197-203. DOI: 10.1001/archpedi.155.11.1197. View

Riddle M, Kastelic E, Frosch E . Pediatric psychopharmacology. J Child Psychol Psychiatry. 2001; 42(1):73-90. View

10.

Walsh B, Seidman S, Sysko R, Gould M . Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002; 287(14):1840-7. DOI: 10.1001/jama.287.14.1840. View

11.

Fost N . Ethical issues in research and innovative therapy in children with mood disorders. Biol Psychiatry. 2001; 49(12):1015-22. DOI: 10.1016/s0006-3223(01)01181-7. View

12.

Emslie G, Rush A, Weinberg W, Kowatch R, Hughes C, Carmody T . A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997; 54(11):1031-7. DOI: 10.1001/archpsyc.1997.01830230069010. View

13.

. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule. Fed Regist. 1999; 63(231):66631-72. View

14.

. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Committee on Drugs, American Academy of Pediatrics. Pediatrics. 1995; 95(2):286-94. View

15.

Farwell J, Lee Y, Hirtz D, Sulzbacher S, Ellenberg J, Nelson K . Phenobarbital for febrile seizures--effects on intelligence and on seizure recurrence. N Engl J Med. 1990; 322(6):364-9. DOI: 10.1056/NEJM199002083220604. View

16.

Keller M, Ryan N, Strober M, Klein R, Kutcher S, Birmaher B . Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001; 40(7):762-72. DOI: 10.1097/00004583-200107000-00010. View

17.

Roberts L, Warner T, Brody J, Roberts B, Lauriello J, Lyketsos C . Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions. Am J Psychiatry. 2002; 159(4):573-84. DOI: 10.1176/appi.ajp.159.4.573. View

18.

. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med. 2001; 344(17):1279-85. DOI: 10.1056/NEJM200104263441703. View

19.

March J, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook E . Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA. 1998; 280(20):1752-6. DOI: 10.1001/jama.280.20.1752. View

20.

Kupfer D, Frank E . Placebo in clinical trials for depression: complexity and necessity. JAMA. 2002; 287(14):1853-4. DOI: 10.1001/jama.287.14.1853. View